RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ResMed Inc (RMD) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive growth trends, and a favorable analyst sentiment. Despite the current pre-market dip, the long-term fundamentals and consistent growth make it a solid investment opportunity.
The technical indicators show mixed signals. The MACD is positive, indicating potential upward momentum, but it is contracting. RSI is neutral at 28.731, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 219.038, and resistance is at 230.984. The stock is currently trading near its support level, suggesting a potential entry point for long-term investors.
Strong financial performance in Q2 2026, with revenue up 10.98% YoY, net income up 13.92% YoY, and EPS up 14.53% YoY.
Analysts maintain positive ratings, with a consensus price target of $292.33, indicating significant upside potential.
ResMed's leadership in the sleep apnea market and consistent average growth rate of 9% over the past two years.
Bearish moving averages and pre-market price decline of -0.89%.
No significant hedge fund or insider trading activity to indicate strong institutional confidence.
In Q2 2026, ResMed reported robust financial growth: Revenue increased to $1.42 billion (+10.98% YoY), Net Income rose to $392.59 million (+13.92% YoY), EPS grew to $2.68 (+14.53% YoY), and Gross Margin improved to 60.93% (+5.52% YoY).
Analysts maintain a positive outlook on ResMed. JPMorgan initiated coverage with an Overweight rating and a price target of A$37.60. Other firms like Citi, RBC Capital, and KeyBanc have maintained Buy or Outperform ratings, with price targets ranging from $255 to $345. The consensus price target is $292.33, indicating significant upside potential.
